Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Infinity Doesn't Sugarcoat Disappointing Duvelisib Data

Executive Summary

Infinity's hopes for accelerated approval of the PI3K inhibitor based on the DYNAMO study have been dashed, so while it plots a new strategy – with or without partner AbbVie – it cuts discovery R&D staff.

Advertisement

Related Content

Key Clinical Data And Drug Approvals Expected In 2H 2016
Infinity Gets More Than A Cash Boost With AbbVie Tie-Up

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register